When early access is strategy and when it is a trap

Early access pathways occupy a deceptively powerful position in European pharmaceutical strategy. They are often discussed as regulatory mechanisms, sometimes as ethical obligations, and increasingly as tactical commercial tools. Rarely are they treated with the strategic seriousness they deserve.

In principle, early access exists for a narrow and defensible reason: to ensure that patients with serious or life-threatening conditions are not denied potentially beneficial therapies while formal regulatory and reimbursement processes are still underway. It is a humanitarian construct, grounded in clinical urgency rather than market ambition.

Early access has drifted far beyond this remit.

Across Europe today, particularly in rare disease, oncology adjacencies, and now increasingly in metabolic and GLP-1 categories, early access is being used as a substitute for strategy. It is positioned as a low-risk bridge into Europe, a way to “start the market” without committing to the cost, complexity, and accountability of a full commercial launch. For some companies, this framing offers comfort and momentum. For many others, it quietly locks in decisions that materially erode long-term value.

The uncomfortable truth is this, early access is neither neutral nor reversible. Once initiated, it creates facts on the ground that shape future pricing, reimbursement, partnering, and regulatory outcomes, often long before leadership teams recognise that strategic optionality has already narrowed.

The illusion of optionality

The most persistent myth surrounding early access is that it preserves flexibility. Boards are frequently told that named patient supply, compassionate use, or early access programmes allow companies to “test Europe” without making binding commitments. The language is always careful, limited volumes, temporary pricing, non-promotional positioning, compassionate intent. The implicit assumption is that these activities exist outside the commercial domain and can therefore be unwound once a formal launch strategy is ready.

This assumption is fundamentally flawed.

Early access creates real patients, real prescribers, real prices, real distribution routes, and real payer awareness. Even when volumes are small, the signal is not. Health systems observe. HTA bodies remember. Pricing authorities do not distinguish between “temporary” and “strategic” prices once they exist in the system. Future partners inherit the market as they find it, not as it was intended.

In effect, early access collapses the distinction between pre-commercial and commercial activity far earlier than most organisations expect. What feels like a cautious first step is often the first irreversible move in a longer strategic sequence.

What early access was actually designed to do

It is important to be precise. Early access is not inherently problematic. When used as intended, it can be an effective and legitimate strategic instrument.

Historically, early access has worked best in settings characterised by severe disease, very small and clinically coherent patient populations, and an absence of meaningful therapeutic alternatives. In these contexts, regulators, clinicians, and payers share a common understanding that early access exists to address urgent unmet medical need rather than to establish market norms.

When early access is successful, several features are almost always present. Patient numbers are tightly controlled. Supply routes are deliberately constrained, often limited to specialist centres. Prices are framed explicitly as provisional and conditional rather than as de facto market signals. Data collection is purposeful, designed to answer specific clinical and economic questions that are known to arise in later HTA assessments. Most importantly, there is a credible and articulated path to marketing authorisation and reimbursement, with early access positioned as a discrete, time-bound phase within a broader European strategy.

In these circumstances, early access behaves less like a commercial launch and more like an extension of development. It builds clinical familiarity and evidentiary confidence without distorting long-term value.

When early access becomes a holding pattern

The strategic risk emerges when early access is used not to support a defined European plan, but to postpone one. This pattern is becoming increasingly common in categories where the commercial opportunity is large, payer environments are uncertain, or internal confidence in launch readiness is low.

In such cases, early access begins to absorb pressures it was never designed to carry. It becomes a release valve for unresolved strategic questions. Rather than forcing clarity on pricing, sequencing, and partnering, it allows these issues to remain unresolved while activity proceeds on the ground.

Over time, this dynamic produces a series of incremental shifts that are individually defensible but collectively damaging. Programmes expand gradually as clinical interest grows. Additional centres are onboarded. Distribution arrangements widen to meet demand. Prices that were initially justified as pragmatic or compassionate begin to function as informal benchmarks. Data is generated, but not always in ways that meaningfully support future HTA narratives.

By the time formal launch planning resumes, the market has already formed expectations that are difficult and sometimes impossible to reset. At this point, early access has ceased to be a bridge and has quietly become the road itself.

The mechanics of value erosion

Value destruction in early access rarely arrives in dramatic fashion. It unfolds through a sequence of small decisions, each rational in isolation, that together narrow strategic freedom.

Price anchoring is one of the most common mechanisms. Even where companies are explicit that early access pricing is temporary, external stakeholders rarely treat it as such. Hospitals and clinicians incorporate these prices into their understanding of what the product is “worth.” HTA bodies may reference them informally when considering cost-effectiveness or budget impact. In systems governed by external reference pricing or most-favoured-nation dynamics, these early prices can cascade across borders in ways that are difficult to predict and even harder to unwind.

Private-pay leakage represents a second, increasingly material risk. In indications with broad or expandable patient populations, such as obesity, metabolic disease, or certain oncology adjacencies, early access supply often migrates into private clinics or out-of-pocket channels. This creates demand growth without payer alignment and invites regulatory scrutiny. More damaging still, it establishes a precedent that payers later use to resist reimbursement, if patients are already accessing the product privately, why should the system pay a premium?

Another frequently underestimated consequence is the erosion of partnering optionality. Potential European partners do not assess assets in isolation; they assess the markets in which those assets already exist. Fragmented distribution, inconsistent pricing, unclear data ownership, and misaligned stakeholder expectations all reduce the attractiveness of a partnership opportunity. What could have been a premium, value-accretive deal becomes a remediation exercise, or fails to progress at all.

Discipline as the differentiator

The difference between early access as a value-creating strategy and early access as a trap is not regulatory sophistication. It is discipline.

Before initiating any early access programme, leadership teams should be able to articulate, with precision, what happens next. This includes a clear view of how early access data will feed into HTA submissions, how pricing decisions today shape pricing outcomes tomorrow, and how operational control will be maintained throughout the process. It also requires an honest assessment of downside scenarios: what happens if timelines slip, if volumes exceed expectations, or if payer sentiment hardens earlier than anticipated.

Where these questions cannot be answered clearly, early access does not buy time. It consumes it, while simultaneously narrowing the range of future strategic options.

In some cases, the most value-protective decision is not to proceed at all. This is particularly true for assets with broad indications, high private-pay appeal, or a strategic imperative to partner. In these situations, restraint is not conservatism. It is strategic intent.

Reframing early access

Early access should be treated with the same rigour applied to pivotal development phases. It should have defined objectives, explicit governance, and a clear endpoint. Success should not be measured by the number of patients treated or the revenue generated, but by whether the programme improves the probability of achieving sustainable reimbursement and long-term value.

When approached in this way, early access can accelerate European strategy and de-risk future negotiations. When treated as a placeholder, a hedge, or an experiment, it often undermines the very outcomes it was meant to support.

The critical question is not whether early access is available. It is whether it is aligned. If an organisation cannot clearly articulate its post-early-access strategy today, it is not ready to initiate early access tomorrow. Early access should serve the strategy it should never become one by default.